Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Xq22.3q23 microdeletion harboring TMEM164 and AMMECR1 genes: Two case reports confirming a recognizable phenotype with short stature, midface hypoplasia, intellectual delay, and elliptocytosis.

Poreau B, Ramond F, Harbuz R, Satre V, Barro C, Vettier C, Adouard V, Thevenon J, Jouk PS, Coutton C, Touraine R, Dieterich K.

Am J Med Genet A. 2019 Apr;179(4):650-654. doi: 10.1002/ajmg.a.61057. Epub 2019 Feb 8.

PMID:
30737907
2.

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response.

Kuhle J, Kropshofer H, Haering DA, Kundu U, Meinert R, Barro C, Dahlke F, Tomic D, Leppert D, Kappos L.

Neurology. 2019 Mar 5;92(10):e1007-e1015. doi: 10.1212/WNL.0000000000007032. Epub 2019 Feb 8.

PMID:
30737333
3.

Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease.

Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, Gräber S, Kuder-Buletta E, LaFougere C, Laske C, Vöglein J, Levin J, Masters CL, Martins R, Schofield PR, Rossor MN, Graff-Radford NR, Salloway S, Ghetti B, Ringman JM, Noble JM, Chhatwal J, Goate AM, Benzinger TLS, Morris JC, Bateman RJ, Wang G, Fagan AM, McDade EM, Gordon BA, Jucker M; Dominantly Inherited Alzheimer Network.

Nat Med. 2019 Feb;25(2):277-283. doi: 10.1038/s41591-018-0304-3. Epub 2019 Jan 21.

PMID:
30664784
4.

Clinical and biological features in PIEZO1-hereditary xerocytosis and Gardos-channelopathy: A retrospective series of 126 patients.

Picard V, Guitton C, Thuret I, Rose C, Bendelac L, Ghazal K, Aguilar-Martinez P, Badens C, Barro C, Bénéteau C, Berger C, Cathébras P, Deconinck E, Delaunay J, Durand JM, Firah N, Galactéros F, Godeau B, Jaïs X, de Jaureguiberry JP, Le Stradic C, Lifermann F, Maffre R, Morin G, Perrin J, Proulle V, Ruivard M, Toutain F, Lahary A, Garçon L.

Haematologica. 2019 Jan 17. pii: haematol.2018.205328. doi: 10.3324/haematol.2018.205328. [Epub ahead of print]

5.

Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity.

Högel H, Rissanen E, Barro C, Matilainen M, Nylund M, Kuhle J, Airas L.

Mult Scler. 2018 Dec 20:1352458518819380. doi: 10.1177/1352458518819380. [Epub ahead of print]

PMID:
30570436
6.

Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis.

Chitnis T, Gonzalez C, Healy BC, Saxena S, Rosso M, Barro C, Michalak Z, Paul A, Kivisakk P, Diaz-Cruz C, Sattarnezhad N, Pierre IV, Glanz BI, Tomic D, Kropshofer H, Häring D, Leppert D, Kappos L, Bakshi R, Weiner HL, Kuhle J.

Ann Clin Transl Neurol. 2018 Oct 16;5(12):1478-1491. doi: 10.1002/acn3.638. eCollection 2018 Dec.

7.

Neurofilament Light Chain: Blood Biomarker of Neonatal Neuronal Injury.

Depoorter A, Neumann RP, Barro C, Fisch U, Weber P, Kuhle J, Wellmann S.

Front Neurol. 2018 Nov 20;9:984. doi: 10.3389/fneur.2018.00984. eCollection 2018.

8.

NfL is a biomarker for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.

Hayer SN, Krey I, Barro C, Rössler F, Körtvelyessy P, Lemke JR, Kuhle J, Schöls L.

Neurology. 2018 Oct 16;91(16):755-757. doi: 10.1212/WNL.0000000000006357. Epub 2018 Sep 14. No abstract available.

PMID:
30217938
9.

Serum neurofilament light: A biomarker of neuroaxonal injury after ischemic stroke.

Tiedt S, Duering M, Barro C, Kaya AG, Boeck J, Bode FJ, Klein M, Dorn F, Gesierich B, Kellert L, Ertl-Wagner B, Goertler MW, Petzold GC, Kuhle J, Wollenweber FA, Peters N, Dichgans M.

Neurology. 2018 Oct 2;91(14):e1338-e1347. doi: 10.1212/WNL.0000000000006282. Epub 2018 Sep 14.

PMID:
30217937
10.

Neurofilaments as biomarkers in neurological disorders.

Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, Barro C, Kappos L, Comabella M, Fazekas F, Petzold A, Blennow K, Zetterberg H, Kuhle J.

Nat Rev Neurol. 2018 Oct;14(10):577-589. doi: 10.1038/s41582-018-0058-z. Review.

PMID:
30171200
11.

Serum Neurofilament Light Chain Levels Are Related to Small Vessel Disease Burden.

Duering M, Konieczny MJ, Tiedt S, Baykara E, Tuladhar AM, Leijsen EV, Lyrer P, Engelter ST, Gesierich B, Achmüller M, Barro C, Adam R, Ewers M, Dichgans M, Kuhle J, de Leeuw FE, Peters N.

J Stroke. 2018 May;20(2):228-238. doi: 10.5853/jos.2017.02565. Epub 2018 May 31.

12.

Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis.

Barro C, Benkert P, Disanto G, Tsagkas C, Amann M, Naegelin Y, Leppert D, Gobbi C, Granziera C, Yaldizli Ö, Michalak Z, Wuerfel J, Kappos L, Parmar K, Kuhle J.

Brain. 2018 Aug 1;141(8):2382-2391. doi: 10.1093/brain/awy154.

PMID:
29860296
13.

Longitudinal MRI dynamics of recent small subcortical infarcts and possible predictors.

Pinter D, Gattringer T, Enzinger C, Seifert-Held T, Kneihsl M, Fandler S, Pichler A, Barro C, Eppinger S, Pirpamer L, Bachmaier G, Ropele S, Wardlaw JM, Kuhle J, Khalil M, Fazekas F.

J Cereb Blood Flow Metab. 2018 May 8:271678X18775215. doi: 10.1177/0271678X18775215. [Epub ahead of print]

PMID:
29737904
14.

Neurofilament as Neuronal Injury Blood Marker in Preeclampsia.

Evers KS, Atkinson A, Barro C, Fisch U, Pfister M, Huhn EA, Lapaire O, Kuhle J, Wellmann S.

Hypertension. 2018 Jun;71(6):1178-1184. doi: 10.1161/HYPERTENSIONAHA.117.10314. Epub 2018 Apr 23.

PMID:
29686016
15.

Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.

Siller N, Kuhle J, Muthuraman M, Barro C, Uphaus T, Groppa S, Kappos L, Zipp F, Bittner S.

Mult Scler. 2018 Mar 1:1352458518765666. doi: 10.1177/1352458518765666. [Epub ahead of print]

PMID:
29542376
16.

Serum neurofilament light chain in patients with acute cerebrovascular events.

De Marchis GM, Katan M, Barro C, Fladt J, Traenka C, Seiffge DJ, Hert L, Gensicke H, Disanto G, Sutter R, Peters N, Sarikaya H, Goeggel-Simonetti B, El-Koussy M, Engelter S, Lyrer PA, Christ-Crain M, Arnold M, Kuhle J, Bonati LH.

Eur J Neurol. 2018 Mar;25(3):562-568. doi: 10.1111/ene.13554. Epub 2018 Jan 24.

17.

Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis.

Feneberg E, Oeckl P, Steinacker P, Verde F, Barro C, Van Damme P, Gray E, Grosskreutz J, Jardel C, Kuhle J, Koerner S, Lamari F, Amador MDM, Mayer B, Morelli C, Muckova P, Petri S, Poesen K, Raaphorst J, Salachas F, Silani V, Stubendorff B, Turner MR, Verbeek MM, Weishaupt JH, Weydt P, Ludolph AC, Otto M.

Neurology. 2018 Jan 2;90(1):e22-e30. doi: 10.1212/WNL.0000000000004761. Epub 2017 Dec 6.

PMID:
29212830
18.

Neurofilament light chain predicts disease activity in relapsing-remitting MS.

Varhaug KN, Barro C, Bjørnevik K, Myhr KM, Torkildsen Ø, Wergeland S, Bindoff LA, Kuhle J, Vedeler C.

Neurol Neuroimmunol Neuroinflamm. 2017 Nov 28;5(1):e422. doi: 10.1212/NXI.0000000000000422. eCollection 2018 Jan.

19.

Serum neurofilament light is sensitive to active cerebral small vessel disease.

Gattringer T, Pinter D, Enzinger C, Seifert-Held T, Kneihsl M, Fandler S, Pichler A, Barro C, Gröbke S, Voortman M, Pirpamer L, Hofer E, Ropele S, Schmidt R, Kuhle J, Fazekas F, Khalil M.

Neurology. 2017 Nov 14;89(20):2108-2114. doi: 10.1212/WNL.0000000000004645. Epub 2017 Oct 18.

20.

Fluid biomarker and electrophysiological outcome measures for progressive MS trials.

Barro C, Leocani L, Leppert D, Comi G, Kappos L, Kuhle J.

Mult Scler. 2017 Oct;23(12):1600-1613. doi: 10.1177/1352458517732844. Review.

PMID:
29041870
21.

Serum neurofilament light chain: a biomarker of neuronal injury in vasculitic neuropathy.

Bischof A, Manigold T, Barro C, Heijnen I, Berger CT, Derfuss T, Kuhle J, Daikeler T.

Ann Rheum Dis. 2018 Jul;77(7):1093-1094. doi: 10.1136/annrheumdis-2017-212045. Epub 2017 Jul 25. No abstract available.

PMID:
28743789
22.

Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.

Disanto G, Barro C, Benkert P, Naegelin Y, Schädelin S, Giardiello A, Zecca C, Blennow K, Zetterberg H, Leppert D, Kappos L, Gobbi C, Kuhle J; Swiss Multiple Sclerosis Cohort Study Group.

Ann Neurol. 2017 Jun;81(6):857-870. doi: 10.1002/ana.24954.

23.

Serum neurofilament is associated with progression of brain atrophy and disability in early MS.

Kuhle J, Nourbakhsh B, Grant D, Morant S, Barro C, Yaldizli Ö, Pelletier D, Giovannoni G, Waubant E, Gnanapavan S.

Neurology. 2017 Feb 28;88(9):826-831. doi: 10.1212/WNL.0000000000003653. Epub 2017 Feb 1.

24.

Neurofilament light chain: a biomarker for genetic frontotemporal dementia.

Meeter LH, Dopper EG, Jiskoot LC, Sanchez-Valle R, Graff C, Benussi L, Ghidoni R, Pijnenburg YA, Borroni B, Galimberti D, Laforce RJ, Masellis M, Vandenberghe R, Ber IL, Otto M, van Minkelen R, Papma JM, Rombouts SA, Balasa M, Öijerstedt L, Jelic V, Dick KM, Cash DM, Harding SR, Jorge Cardoso M, Ourselin S, Rossor MN, Padovani A, Scarpini E, Fenoglio C, Tartaglia MC, Lamari F, Barro C, Kuhle J, Rohrer JD, Teunissen CE, van Swieten JC.

Ann Clin Transl Neurol. 2016 Jul 1;3(8):623-36. doi: 10.1002/acn3.325. eCollection 2016 Aug.

25.

Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum.

Wilke C, Preische O, Deuschle C, Roeben B, Apel A, Barro C, Maia L, Maetzler W, Kuhle J, Synofzik M.

J Neurol Neurosurg Psychiatry. 2016 Nov;87(11):1270-1272. doi: 10.1136/jnnp-2015-312972. Epub 2016 May 17. No abstract available.

PMID:
27188986
26.

Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa.

Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius Å, Liman V, Norgren N, Blennow K, Zetterberg H.

Clin Chem Lab Med. 2016 Oct 1;54(10):1655-61. doi: 10.1515/cclm-2015-1195.

PMID:
27071153
27.

Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity.

Kuhle J, Barro C, Disanto G, Mathias A, Soneson C, Bonnier G, Yaldizli Ö, Regeniter A, Derfuss T, Canales M, Schluep M, Du Pasquier R, Krueger G, Granziera C.

Mult Scler. 2016 Oct;22(12):1550-1559. Epub 2016 Jan 11.

PMID:
26754800
28.

[Management of thrombotic thrombocytopenic purpura in two French centers: A series of 27 patients].

Deroux A, Sirodot M, Daguindau N, Barro C, Coppo P, Bouillet L.

Rev Med Interne. 2016 Jan;37(1):13-8. doi: 10.1016/j.revmed.2015.05.003. Epub 2015 Jun 9. French.

PMID:
26065327
29.

Neurofilament Light Chain Determination from Peripheral Blood Samples.

Limberg M, Disanto G, Barro C, Kuhle J.

Methods Mol Biol. 2016;1304:93-8. doi: 10.1007/7651_2015_206.

PMID:
25687302
30.

Long-term therapy with bevacizumab in a patient with Glanzmann's thrombasthenia and recurrent digestive bleeding due to gastrointestinal angiodysplastic lesions.

Marlu R, Barthelon J, Durand A, Mathieu N, Barro C, Granger V, Tatu A, Pernod G, Polack B, Bonaz B.

Am J Gastroenterol. 2015 Feb;110(2):352-3. doi: 10.1038/ajg.2014.391. No abstract available.

PMID:
25646919
31.

HBB loss of heterozygosity in the hemopoietic lineage gives rise to an unusual sickle-cell trait phenotype.

Joly P, Schluth-Bolard C, Lacan P, Barro C, Pissard S, Labalme A, Sanlaville D, Badens C.

Haematologica. 2013 Jan;98(1):e7-8. doi: 10.3324/haematol.2012.071167. Epub 2012 Oct 12. No abstract available.

32.

A new Frameshift mutation on the α2-globin gene causing α⁺-thalassemia: codon 43 (TTC>-TC or TTC>T-C).

Joly P, Lacan P, Garcia C, Barro C, Francina A.

Hemoglobin. 2012;36(5):508-10.

PMID:
22738776
33.

[Risk groups in differentiated thyroid carcinomas].

Herránz González-Botas J, Barro CV, Vidal JM.

Acta Otorrinolaringol Esp. 2011 Jan-Feb;62(1):14-9. doi: 10.1016/j.otorri.2010.09.007. Epub 2010 Nov 26. Spanish.

34.

Two new G gamma chain variants: Hb F-Saint-Etienne [G gamma 79(EF3)Asp-->His] and Hb F-Lyon [G gamma 97(FG4)His-->Arg].

Joly P, Lacan P, Garcia C, Berger C, Perier C, Barro C, Francina A.

Hemoglobin. 2008;32(5):491-7. doi: 10.1080/03630260802341653.

PMID:
18932075
35.

Should plasma homocysteine be used as a biomarker of venous thromboembolism? A case-control study.

Ducros V, Barro C, Yver J, Pernod G, Polack B, Carpentier P, Desruet MD, Bosson JL.

Clin Appl Thromb Hemost. 2009 Oct;15(5):517-22. doi: 10.1177/1076029608322548. Epub 2008 Sep 25.

PMID:
18818229
36.

Discordant D-dimer results of two rapid quantitative automated assays are related to age.

Barro C, Bosson JL, Satger B, Polack B, Pernod G.

J Thromb Haemost. 2008 Nov;6(11):1970-1. doi: 10.1111/j.1538-7836.2008.03149.x. Epub 2008 Aug 30. No abstract available.

37.

Two new alpha-thalassemia point mutations that are undetectable by biochemical techniques.

Joly P, Pégourie B, Courby S, Barro C, Besson G, Cohen L, Garcia C, Francina A.

Hemoglobin. 2008;32(4):411-7. doi: 10.1080/03630260802173791.

PMID:
18654892
38.

The paradoxical association between inherited factor VII deficiency and venous thrombosis.

Marty S, Barro C, Chatelain B, Fimbel B, Tribout B, Reynaud J, Schved JF, Giansily-Blaizot M.

Haemophilia. 2008 May;14(3):564-70. doi: 10.1111/j.1365-2516.2007.01647.x. Epub 2008 Feb 13.

PMID:
18282149
39.

Phenotypic and genotypic risk factors for cardiovascular events in an incident dialysis cohort.

Pernod G, Bosson JL, Golshayan D, Barro C, Forneris G, Martina G, Bonfant G, Hurot JM, Turc-Baron C, Jouet C, Theytaz J, Jeantet A, Wauters JP, Cordonnier D; Diamant Alpin Collaborative Dialysis Study Group.

Kidney Int. 2006 Apr;69(8):1424-30.

40.

Impact of phenolic compounds and related enzymes in sorghum varieties for resistance and susceptibility to biotic and abiotic stresses.

Dicko MH, Gruppen H, Barro C, Traore AS, van Berkel WJ, Voragen AG.

J Chem Ecol. 2005 Nov;31(11):2671-88. Epub 2005 Oct 25.

PMID:
16273434
41.
42.

Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis.

Mossuz P, Girodon F, Donnard M, Latger-Cannard V, Dobo I, Boiret N, Lecron JC, Binquet C, Barro C, Hermouet S, Praloran V.

Haematologica. 2004 Oct;89(10):1194-8.

43.

The Diamant Alpin Dialysis cohort study: clinico-biological characteristics and cardiovascular genetic risk profile of incident patients.

Pernod G, Bosson JL, Golshayan D, Barro C, Alloatti S, Turc-Baron C, Quarello F, Jeantet A, Von Albertini B, Forêt M, Lauren G, Cordonnier D, Piccoli G, Wauters JP; Diamant Alpin Collaborative Dialysis Study Group.

J Nephrol. 2004 Jan-Feb;17(1):66-75.

PMID:
15151261
44.

Successful use of recombinant factor VIIa for severe surgical liver bleeding in a 5 month-old baby.

Barro C, Wrobleski I, Piolat C, Cartal M, Dyon JF, Jacquier C, Andrini P, Polack B, Pernod G.

Haemophilia. 2004 Mar;10(2):183-5.

PMID:
14962209
45.

[Routine preoperative evaluation of hemostasis].

Pernod G, Barro C, Blanc-Jouvan F, Polack B.

Rev Stomatol Chir Maxillofac. 2003 Apr;104(2):91-7. Review. French.

PMID:
12750626
46.

Surgery in severe factor XIII deficiency: report of a case of epilepsy neurosurgery and review.

Pernod G, Barro C, Arnutti B, Blanc-Jouvan F, Garrel S, Kahn P, Minotti L, Koudsie A, Benabid AL, Wrobleski I, Joannard A, Polack B.

Haemophilia. 2003 Jan;9(1):121-4.

PMID:
12558790
47.

[Place of homocysteinemia in the treatment and the follow-up of lower-limb artherosclerotic disease].

Sessa C, Pénillon S, Aubert A, Barro C, Ducros V, Pêcher M, Guidicelli H, Magne JL.

Ann Biol Clin (Paris). 2002 May-Jun;60(3):327-9. French. No abstract available.

48.

[Homocysteinemia and recurrent fetal losses: description of three cases].

Barro C, Ducros V, Bonaz B, Muet F, Quenard N, Fontaine M, Polack B, Pernod G.

Ann Biol Clin (Paris). 2002 May-Jun;60(3):325-6. French. No abstract available.

49.

Dehydrated hereditary stomatocytosis: a cause of prenatal ascites.

Grootenboer S, Barro C, Cynober T, Olivier Schischmanoff P, Ayoubi JM, Tchernia G, Delaunay J, Pons JC.

Prenat Diagn. 2001 Dec;21(13):1114-8.

PMID:
11787034
50.

Hb Diamant [alpha119(H2)Pro-->Leu]: a new variant with a modification at the alpha1beta1 interface.

Préhu C, Riou J, Godart C, Bost M, Barro C, Promé D, Kister J, Galactéros F, Wajcman H.

Hemoglobin. 2000 Aug;24(3):249-52. No abstract available.

PMID:
10975445

Supplemental Content

Support Center